Literature DB >> 23419135

Evaluating a combined (frequency and percentage) risk expression to communicate information on medicine side effects to patients.

Peter Knapp1, Peter Gardner, Brian McMillan, David K Raynor, Elizabeth Woolf.   

Abstract

OBJECTIVES: The study evaluated the interpretation of, and preferences for, numerical information on side-effect incidence when presented in three different formats.
METHODS: It used a controlled design, with participants allocated at random to receive one of the three formats. Participants were recruited via a pop-up window on the CancerHelp UK website. The sample comprised 129 website users, of whom 96% were women and 86% had cancer, who received frequency information on four side effects of tamoxifen, using one of three risk expressions (percentages, e.g. 'affects 25% of people'; frequencies, e.g. 'affects 1 in 4 people'; combined, e.g. 'affects 1 in 4 people (25%)'). They then interpreted information on tamoxifen and its effect on health, and estimates of side-effect frequency, and then stated a preference from the three risk expression formats. KEY
FINDINGS: The results showed that the three formats did not influence participants' ratings of the information or their side-effect estimates. However, more than half (53%) the participants preferred the combined (frequency and percentage) format. In conclusion, a combined risk expression format performed no worse than percentages or frequencies alone and was preferred by a majority.
CONCLUSIONS: The three risk expression formats did not differ in their effect on participants' interpretations. However, the preferred format was the combined (frequency and percentage) risk expression.
© 2012 The Authors. IJPP © 2012 Royal Pharmaceutical Society.

Entities:  

Keywords:  RCT; harm; information; medicines; risk; tamoxifen

Mesh:

Substances:

Year:  2012        PMID: 23419135     DOI: 10.1111/j.2042-7174.2012.00254.x

Source DB:  PubMed          Journal:  Int J Pharm Pract        ISSN: 0961-7671


  7 in total

1.  Combined verbal and numerical expressions increase perceived risk of medicine side-effects: a randomized controlled trial of EMA recommendations.

Authors:  Peter Knapp; Peter H Gardner; Elizabeth Woolf
Journal:  Health Expect       Date:  2015-01-26       Impact factor: 3.377

2.  Medication risk communication with cancer patients in a Middle East cancer care setting.

Authors:  Kerry Wilbur; Maha Al-Okka; Ebaa Jumaat; Nesma Eissa; Merwa Elbashir; Sumaya M Al Saadi Al-Yafei
Journal:  Patient Prefer Adherence       Date:  2016-04-22       Impact factor: 2.711

3.  Exploring consumer opinions on the presentation of side-effects information in Australian Consumer Medicine Information leaflets.

Authors:  Vivien Tong; David K Raynor; Susan J Blalock; Parisa Aslani
Journal:  Health Expect       Date:  2014-06-06       Impact factor: 3.377

4.  Cocreation with Dutch patients of decision-relevant information to support shared decision-making about adjuvant treatment in breast cancer care.

Authors:  Inge S van Strien-Knippenberg; Marieke C S Boshuizen; Domino Determann; Jasmijn H de Boer; Olga C Damman
Journal:  Health Expect       Date:  2022-05-17       Impact factor: 3.318

5.  The effect of public reporting presentation on patients' decision making: An experimental survey in Yunan Province, China.

Authors:  Chenxi Liu; Yuqing Tang; Dan Wang; Xinping Zhang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

6.  Communicating treatment risks and benefits to cancer patients: a systematic review of communication methods.

Authors:  L F van de Water; J J van Kleef; W P M Dijksterhuis; I Henselmans; H G van den Boorn; N M Vaarzon Morel; K F Schut; J G Daams; E M A Smets; H W M van Laarhoven
Journal:  Qual Life Res       Date:  2020-04-24       Impact factor: 4.147

Review 7.  A systematic review of factors associated with side-effect expectations from medical interventions.

Authors:  Louise E Smith; Rebecca K Webster; G James Rubin
Journal:  Health Expect       Date:  2020-04-13       Impact factor: 3.377

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.